Janssen obtains FDA approval for Ponvory

The Food and Drug Administration has given the green light to Janssen for Ponvory (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 modulator, to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

"MS is a complex disease, and any individual's response to MS disease-modifying therapy can vary," said  Bruce Bebo, executive vice president of Research at the National MS Society. "It's so important that people living with MS have access to effective treatment options. We are pleased that there is a new therapy approved for relapsing MS."

"Every person with multiple sclerosis is affected differently, given the variability in both the underlying disease and emerging symptoms. Continued innovation in this space is critical, and we're committed to meeting patients' evolving healthcare needs," said Mathai Mammen, global head, Janssen Research & Development, Johnson & Johnson. "We are proud to offer Ponvory as a valuable new option for people with MS that may help them gain better control of their disease."